Skip to main content

Table 2 Clinical-pathological features of Cohort II pLGG patients

From: MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression

Cohort II pLGG patients
Sample code Age (years) Gender Site of onset Histology Type of resection Progression Progression Free Survival (months) Overall Survival (months) Mutational status
ICGC_PA104 3 F Md Supra PA NTR W/O 6 6 WT
ICGC_PA144 2 F Md Supra PA NTR W/O 4 4 CLCN6:BRAF Ex2:Ex11); BRAF p.E451D
ICGC_PA14 5 F Md Supra PA NTR W/O 23 23 K15B9
ICGC_PA159 5 M Md Supra PA NTR W/O 3 3 QKI:NTRK2 (Ex6:Ex16)
ICGC_PA4 1 M Md Supra PA NTR W/O 22 22 K16B9
ICGC_PA54 4 F Md Supra PA NTR WITH 4 12 WT
ICGC_PA69 6 F Md Supra PA NTR WITH 17 17 NF1 Large deletion (somatic); p.Q1174fs (somatic); FGFR1 p.N546K
ICGC_PA71 2 F Md Supra PA NTR WITH 5 16 NF1 p.Q959X (germline); large deletion (somatic)
ICGC_PA84 9 M Md Supra PA NTR W/O 10 10 FGFR1 p.K656E; PTPN11 p.E76A
  1. Md Midline, PA Pilocytic Astrocytoma, NTR Near Total Resection, WITH With progression, W/O Without progression